Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Preferred Stock Liabilities: 2023-2024

  • Camp4 Therapeutics' Preferred Stock Liabilities changed negligibly% to $162.1 million in Q3 2024 from the same period last year, while for Sep 2024 it was $162.1 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $162.1 million for FY2023, which is N/A change from last year.
  • Latest data reveals that Camp4 Therapeutics reported Preferred Stock Liabilities of $162.1 million as of Q3 2024, which was down 0.00% from $162.1 million recorded in Q4 2023.
  • In the past 5 years, Camp4 Therapeutics' Preferred Stock Liabilities registered a high of $162.1 million during Q3 2023, and its lowest value of $162.1 million during Q3 2023.
  • Over the past 2 years, Camp4 Therapeutics' median Preferred Stock Liabilities value was $162.1 million (recorded in 2024), while the average stood at $162.1 million.